Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Executive Summary
Alzheimer's disease, amyotrophic lateral sclerosis, migraine, and opioid dependence are among conditions that will get drug development guides from FDA; other guidances will address ANDA bioequivalence studies, shared REMS, and continuous manufacturing.
You may also be interested in...
Refuse-to-File Turns 25: New Guidance Changes In Style, But Not Substance
US FDA’s revised draft guidance spelling out its policy on 'refuse-to-file' decisions differs little in substance compared to predecessor issued in 1993. But difference in style is telling sign of the times.
US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products
Draft is intended to inform development of non-testosterone products such as aromatase inhibitors or estrogen receptor agonists.
Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says
Generic applications continue to be tripped up by failing to adhere to other well-known standards such as paying user fees, US agency says.